CN112654612A - 作为抗肿瘤剂的喹唑啉衍生物 - Google Patents
作为抗肿瘤剂的喹唑啉衍生物 Download PDFInfo
- Publication number
- CN112654612A CN112654612A CN201980044137.8A CN201980044137A CN112654612A CN 112654612 A CN112654612 A CN 112654612A CN 201980044137 A CN201980044137 A CN 201980044137A CN 112654612 A CN112654612 A CN 112654612A
- Authority
- CN
- China
- Prior art keywords
- pyrimidin
- yloxy
- triazolo
- methylphenyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410230537.0A CN118255772A (zh) | 2018-09-18 | 2019-09-17 | 作为抗肿瘤剂的喹唑啉衍生物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018106098 | 2018-09-18 | ||
| CNPCT/CN2018/106098 | 2018-09-18 | ||
| CNPCT/CN2019/091078 | 2019-06-13 | ||
| CN2019091078 | 2019-06-13 | ||
| PCT/CN2019/106233 WO2020057511A1 (en) | 2018-09-18 | 2019-09-17 | Quinazoline derivatives as antitumor agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410230537.0A Division CN118255772A (zh) | 2018-09-18 | 2019-09-17 | 作为抗肿瘤剂的喹唑啉衍生物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112654612A true CN112654612A (zh) | 2021-04-13 |
Family
ID=69888359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980044137.8A Pending CN112654612A (zh) | 2018-09-18 | 2019-09-17 | 作为抗肿瘤剂的喹唑啉衍生物 |
| CN202410230537.0A Pending CN118255772A (zh) | 2018-09-18 | 2019-09-17 | 作为抗肿瘤剂的喹唑啉衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410230537.0A Pending CN118255772A (zh) | 2018-09-18 | 2019-09-17 | 作为抗肿瘤剂的喹唑啉衍生物 |
Country Status (19)
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111377850A (zh) * | 2018-12-31 | 2020-07-07 | 扬州氟药科技有限公司 | 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法 |
| CN115650977A (zh) * | 2022-10-09 | 2023-01-31 | 广东润兴生物科技有限公司 | 一种妥卡替尼的合成方法 |
| WO2023066296A1 (en) * | 2021-10-20 | 2023-04-27 | Suzhou Zanrong Pharma Limited | Crystalline forms of quinazoline derivatives, preparation, composition and use thereof |
| CN116478129A (zh) * | 2022-01-21 | 2023-07-25 | 深圳默元生物科技有限公司 | 喹啉化合物及其用途 |
| WO2023185793A1 (zh) * | 2022-03-28 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| WO2024213045A1 (en) * | 2023-04-14 | 2024-10-17 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Pharmaceutical forms of quinazoline erbb inhibitors |
| WO2025067396A1 (zh) * | 2023-09-27 | 2025-04-03 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的可药用盐、其结晶形式及用途 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚(上海)生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚(上海)生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| HRP20240293T1 (hr) * | 2018-09-18 | 2024-05-24 | F. Hoffmann - La Roche Ag | Derivati kinazolina kao protutumorska sredstva |
| CN113527215B (zh) * | 2020-04-17 | 2023-12-05 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| WO2021209039A1 (zh) * | 2020-04-17 | 2021-10-21 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Her2突變抑制劑 |
| JP7598180B2 (ja) * | 2021-03-19 | 2024-12-11 | 北京賽特明強医薬科技有限公司 | キナゾリン系化合物、キナゾリン系化合物の組成物及び応用 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN117940424A (zh) * | 2021-06-22 | 2024-04-26 | 缆图药品公司 | Egfr抑制剂 |
| WO2022271749A1 (en) * | 2021-06-22 | 2022-12-29 | Blueprint Medicines Corporation | Heterocyclic egfr inhibitors for use in the treatment of cancer |
| US20240382483A1 (en) * | 2021-06-22 | 2024-11-21 | Blueprint Medicines Corporation | Heterocyclic egfr inhibitors for use in the treatment of cancer |
| CN117836286A (zh) | 2021-06-22 | 2024-04-05 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| CN115894383B (zh) * | 2021-09-30 | 2025-12-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| CA3245866A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof |
| WO2024249642A1 (en) * | 2023-06-02 | 2024-12-05 | Acerand Therapeutics (Hong Kong) Limited | Egfr inhibitors |
| TW202602446A (zh) | 2024-03-19 | 2026-01-16 | 瑞士商豪夫邁 羅氏有限公司 | Erbb2抑制劑的藥物製劑 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101356171A (zh) * | 2005-11-15 | 2009-01-28 | 阿雷生物药品公司 | 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物 |
| CN107141293A (zh) * | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| WO2018055023A1 (en) * | 2016-09-22 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003357A1 (en) | 1984-01-30 | 1985-08-01 | Icrf Patents Ltd. | Improvements relating to growth factors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| EP0494135B1 (en) | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| CN1437594A (zh) | 2000-06-22 | 2003-08-20 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| RU2004116911A (ru) * | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2004000529A1 (de) | 2002-06-24 | 2003-12-31 | Fagerdala Deutschland Gmbh | Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP4828421B2 (ja) | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| KR20090090336A (ko) * | 2006-12-12 | 2009-08-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합된 헤테로시클릭 화합물 |
| CN109422755B (zh) | 2017-09-01 | 2023-07-04 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| CN111630046B (zh) * | 2017-12-19 | 2023-01-10 | 成都金瑞基业生物科技有限公司 | 喹唑啉衍生物及其应用 |
| WO2019214651A1 (zh) * | 2018-05-08 | 2019-11-14 | 南京明德新药研发有限公司 | 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 |
| TWI811358B (zh) | 2018-05-08 | 2023-08-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | ErbB受體抑制劑 |
| HRP20240293T1 (hr) * | 2018-09-18 | 2024-05-24 | F. Hoffmann - La Roche Ag | Derivati kinazolina kao protutumorska sredstva |
-
2019
- 2019-09-17 HR HRP20240293TT patent/HRP20240293T1/hr unknown
- 2019-09-17 JP JP2021514381A patent/JP7546550B2/ja active Active
- 2019-09-17 DK DK19862146.8T patent/DK3853220T3/da active
- 2019-09-17 HU HUE23219357A patent/HUE069764T2/hu unknown
- 2019-09-17 SM SM20240524T patent/SMT202400524T1/it unknown
- 2019-09-17 EP EP23219357.3A patent/EP4360713B1/en active Active
- 2019-09-17 ES ES19862146T patent/ES2971927T3/es active Active
- 2019-09-17 PL PL23219357.3T patent/PL4360713T3/pl unknown
- 2019-09-17 PL PL19862146.8T patent/PL3853220T3/pl unknown
- 2019-09-17 LT LTEP23219357.3T patent/LT4360713T/lt unknown
- 2019-09-17 SI SI201930872T patent/SI4360713T1/sl unknown
- 2019-09-17 KR KR1020257038595A patent/KR20250171398A/ko active Pending
- 2019-09-17 CN CN201980044137.8A patent/CN112654612A/zh active Pending
- 2019-09-17 RS RS20240267A patent/RS65413B1/sr unknown
- 2019-09-17 EP EP19862146.8A patent/EP3853220B1/en active Active
- 2019-09-17 HR HRP20241743TT patent/HRP20241743T1/hr unknown
- 2019-09-17 FI FIEP23219357.3T patent/FI4360713T3/fi active
- 2019-09-17 AU AU2019341273A patent/AU2019341273B2/en active Active
- 2019-09-17 PT PT232193573T patent/PT4360713T/pt unknown
- 2019-09-17 WO PCT/CN2019/106233 patent/WO2020057511A1/en not_active Ceased
- 2019-09-17 LT LTEPPCT/CN2019/106233T patent/LT3853220T/lt unknown
- 2019-09-17 RS RS20241396A patent/RS66314B1/sr unknown
- 2019-09-17 DK DK23219357.3T patent/DK4360713T3/da active
- 2019-09-17 KR KR1020217003251A patent/KR102889933B1/ko active Active
- 2019-09-17 EP EP24208940.7A patent/EP4523755A3/en active Pending
- 2019-09-17 FI FIEP19862146.8T patent/FI3853220T3/fi active
- 2019-09-17 ES ES23219357T patent/ES3007082T3/es active Active
- 2019-09-17 US US17/051,176 patent/US11723908B2/en active Active
- 2019-09-17 HU HUE19862146A patent/HUE065578T2/hu unknown
- 2019-09-17 CN CN202410230537.0A patent/CN118255772A/zh active Pending
- 2019-09-17 CA CA3099776A patent/CA3099776A1/en active Pending
- 2019-09-17 SI SI201930718T patent/SI3853220T1/sl unknown
- 2019-09-17 PT PT198621468T patent/PT3853220T/pt unknown
-
2023
- 2023-05-18 US US18/319,509 patent/US20230293533A1/en not_active Abandoned
-
2024
- 2024-07-15 AU AU2024204847A patent/AU2024204847A1/en active Pending
- 2024-07-26 JP JP2024120830A patent/JP2024164018A/ja not_active Withdrawn
-
2025
- 2025-09-11 JP JP2025150799A patent/JP2026009898A/ja active Pending
-
2026
- 2026-07-07 AU AU2026205380A patent/AU2026205380A1/en active Pending
- 2026-07-17 AU AU2026206192A patent/AU2026206192A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101356171A (zh) * | 2005-11-15 | 2009-01-28 | 阿雷生物药品公司 | 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物 |
| CN107141293A (zh) * | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| WO2018055023A1 (en) * | 2016-09-22 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111377850A (zh) * | 2018-12-31 | 2020-07-07 | 扬州氟药科技有限公司 | 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法 |
| CN111377850B (zh) * | 2018-12-31 | 2022-10-18 | 艾琪康医药科技(上海)有限公司 | 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法 |
| WO2023066296A1 (en) * | 2021-10-20 | 2023-04-27 | Suzhou Zanrong Pharma Limited | Crystalline forms of quinazoline derivatives, preparation, composition and use thereof |
| CN119317625A (zh) * | 2021-10-20 | 2025-01-14 | 豪夫迈·罗氏有限公司 | 喹唑啉衍生物的结晶形式、其制备、组合物和用途 |
| CN116478129A (zh) * | 2022-01-21 | 2023-07-25 | 深圳默元生物科技有限公司 | 喹啉化合物及其用途 |
| CN116478129B (zh) * | 2022-01-21 | 2025-01-07 | 深圳默元生物科技有限公司 | 喹啉化合物及其用途 |
| WO2023185793A1 (zh) * | 2022-03-28 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| CN115650977A (zh) * | 2022-10-09 | 2023-01-31 | 广东润兴生物科技有限公司 | 一种妥卡替尼的合成方法 |
| WO2024213045A1 (en) * | 2023-04-14 | 2024-10-17 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Pharmaceutical forms of quinazoline erbb inhibitors |
| WO2025067396A1 (zh) * | 2023-09-27 | 2025-04-03 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的可药用盐、其结晶形式及用途 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230293533A1 (en) | Quinazoline derivatives as antitumor agents | |
| AU2023272945A1 (en) | Aza-tetracyclic oxazepine compounds and uses thereof | |
| ES2835729T3 (es) | Terapias de combinación para el tratamiento de cáncer | |
| JP2025530170A (ja) | Kras g12d阻害剤 | |
| WO2020253862A1 (zh) | 含氮芳基磷氧化物类衍生物、其制备方法和应用 | |
| JP7706585B2 (ja) | 毛細血管拡張性運動失調症変異(ATM)キナーゼの選択的調節物質としての1-イソプロピル-3-メチル-8-(ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オンおよびその使用 | |
| AU2025203211A1 (en) | ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS | |
| HK40108721A (en) | Quinazoline derivatives as antitumor agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250908 Address after: Basel Applicant after: F. HOFFMANN-LA ROCHE AG Country or region after: Switzerland Address before: 215000 Jiangsu Province Suzhou City Industrial Park Xinghu Street 218 Biomedical Industry Park Building B6 2nd Floor Room R2019 Applicant before: Suzhou zanrong Medical Technology Co.,Ltd. Country or region before: China |